LL-37: Broad-Spectrum Host Defense and Immune Modulation

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Overview

LL-37 is the sole human cathelicidin-derived antimicrobial peptide (AMP). Stored as the inactive precursor hCAP18 in neutrophil granules and released upon cleavage by proteases (e.g., neutrophil elastase/proteinase 3), LL-37 is produced by multiple cell types—including neutrophils, epithelial cells of skin and mucosa, and myeloid precursors—and is detectable across oral, gastrointestinal, pulmonary, and reproductive tissues. Cutaneous vitamin D signaling can upregulate LL-37 expression, linking barrier immunity to environmental cues (sunlight).

Functionally, LL-37 provides rapid, front-line defense against bacteria, enveloped viruses, and fungi while also shaping downstream immune responses. Its biology is context-dependent: the same peptide that promotes antimicrobial clearance and wound repair can, when dysregulated, contribute to inflammatory pathology (e.g., psoriasis, mucus hypersecretion in COPD).

Where and How LL-37 Acts

• Tissue distribution: circulating neutrophils and bone-marrow myeloid cells; skin, bronchial and colonic mucosa; squamous epithelium of the mouth, tongue, and esophagus; epididymis; lungs; GI tract.

• Induction: inflammatory stimuli and microbial products; vitamin D–dependent pathways in macrophages and keratinocytes.
  

Mechanisms of Action

1) Direct antimicrobial activity

LL-37 is a cationic, amphipathic α-helical peptide that disrupts microbial envelopes. Unlike classic barrel-stave or toroidal pore models—or the “carpet” mechanism alone—LL-37 often remains aligned parallel to the membrane surface and perturbs lipid organization without necessarily fragmenting bilayers. Reported minimum inhibitory concentrations (MIC 1–10 μM) span Gram-positive and Gram-negative bacteria; at higher concentrations (≈13–25 μM) eukaryotic cytotoxicity can emerge, underscoring dose- and context-dependence.

2) Indirect immunomodulation

LL-37 orchestrates innate and adaptive responses:

• Pro-inflammatory signaling when needed: recruits leukocytes, drives M1 macrophage polarization, promotes inflammasome activation, and supports type-I interferon programs during acute infection.
  
• Resolution and tissue protection: neutralizes LPS to dampen TLR4 activation; down-modulates excessive cytokine output; strengthens epithelial barriers by increasing stiffness and decreasing permeability; inhibits biofilm attachment and maturation.
  

What the Research Shows

• Broad antimicrobial scope: active against diverse bacteria, enveloped viruses (e.g., influenza A, RSV), and fungi (e.g., Candida albicans).
  
• Barrier fortification: increases epithelial stiffness and reduces paracellular permeability to limit pathogen translocation.
  
• Biofilm control: interferes with device-associated pathogens (e.g., Staphylococcus epidermidis) by reducing attachment and biofilm formation.
  
• Host-directed therapy potential: adjunct or alternative strategy where antibiotic resistance or intracellular persistence limits standard care.
  

Selected Research Domains (Expanded)

Bacterial defense

LL-37 reduces attachment and biofilm production by S. epidermidis, supporting strategies to prevent device-related infections. Against S. aureus, LL-37 can eliminate both extra- and intracellular bacteria more rapidly than certain comparators in vitro, suggesting utility for chronic or recurrent infections where intracellular reservoirs persist.

Antiviral and antifungal activity

Against influenza A, LL-37 perturbs the viral envelope without inducing the aggregation seen with some collectins/defensins. In Candida albicans, LL-37 disrupts cell-wall integrity and alters gene expression programs tied to growth and replication, contributing to antifungal effects.

Respiratory syncytial virus (RSV)

LL-37 damages RSV particles, impairs epithelial binding, and lowers viral survival/replication. In vivo models show exogenous LL-37 can mitigate RSV-mediated lung disease; human challenge studies associate higher nasal LL-37 levels with infection control—implicating LL-37 as a first-line, inducible antiviral mediator.

Reproductive health (contraceptive concept)

LL-37 naturally occurs in the female reproductive tract and exhibits antimicrobial activity against sexually transmitted pathogens. In vitro, LL-37 binding to sperm heads can dose-dependently inhibit fertilization while remaining non-toxic to vaginal and cervical cell lines—supporting exploration of dual-purpose, topical antimicrobial-contraceptive strategies.

Respiratory disease

Low circulating LL-37 correlates with a higher risk of infectious exacerbations in COPD. Conversely, LL-37 can drive mucus hypersecretion via TACE–EGFR–ERK signaling and promote fibroblast activity, potentially worsening obstruction. These dual roles highlight the importance of local dosing, timing, and patient selection.

Gastrointestinal tract

LL-37 expression increases in inflamed mucosa in ulcerative colitis/Crohn’s disease (via TLR3/TLR9 pathways). It neutralizes LPS, supports antimicrobial defense, and exhibits antifibrotic tendencies—yet excessive or chronic induction may contribute to fibrosis signaling in some settings.

Skin and wound healing

Topical vitamin D analogs enhance LL-37 upregulation after injury, improving antimicrobial defense and re-epithelialization. In psoriasis, LL-37 can become an autoantigen, activating LL-37-specific T cells and amplifying type-1/Th17 inflammation—an example of protective AMP biology tipping into pathogenic autoimmunity when dysregulated.

Oncology (GI tract)

LL-37 demonstrates tumor-suppressive activity in preclinical models by activating a GPCR–p53–Bax/Bak/Bcl-2 axis leading to caspase-independent, AIF/EndoG-mediated apoptosis in colon cancer cells, and by engaging BMP signaling with Smad1/5 phosphorylation and p21 induction in gastric cancer cells.

Practical Considerations

• Therapeutic window matters: efficacy and epithelial protection occur below thresholds that risk host-cell toxicity.
  
• Context is key: benefits (antimicrobial, barrier repair, immune tuning) must be balanced against risks of over-activation (psoriasis, mucus hypersecretion).
  
• Translational outlook: optimization of analogs/derivatives, formulation for targeted delivery (e.g., mucosal surfaces, wounds), and controlled induction (e.g., vitamin D pathways) are active areas of investigation.
  

Conclusion

LL-37 is a versatile host-defense peptide with direct antimicrobial effects and powerful immunomodulatory capacity. It can enhance barrier integrity, disrupt biofilms, and coordinate innate and adaptive responses across skin, airway, gut, and reproductive mucosa. At the same time, dysregulated or excessive LL-37 activity can fuel inflammatory disease. Ongoing research into dosing, delivery, and pathway targeting aims to harness LL-37’s protective biology while minimizing unintended immune activation.

References

Kosciuczuk E. Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep. 2012 Dec; 39(12): 10957 –10970. Published online 2012 Oct 14.

Neville; et al. Lipid Headgroup Discrimination by Antimicrobial Peptide LL-37: Insight in Mechanism of Action.

Wildman; et al. Mechanism of Lipid Bilayer Disruption by the Human Antimicrobial Peptide, LL-37. Biochemistry 2003, 42, 6545-6558.

Tanaka; et al. Sensitivity of Actinobacillus actinomyecetemcomitans and Capnocytophaaga spp. To the bactericidal action of LL-37: a cathelicidin found in human leukocytes and epithelium. Oral Microbiol Immunol. 200 Aug;15(4):226-31.

Henzler-Wildman KA; et al. Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37. Biochemistry. 2004 Jul 6;43(26):8459-69.

Barns; Weisshaar. Real-time Attack of LL-37 on Single Bacillus subtilis Cells. Biochim Biophys Acta. 2013

Hell; et al. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett Appl Microbiol. 2010 Feb;50(2):211-5. 2009 Nov 23.

Noore j. Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular staphylococcus aureus.

Tripathi, S; et al. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D of defensins. Journal of General Virology (2013), 94, 40-49.

Tsai PW; et al. Responses of Candida albicans to the human antimicrobial peptide LL-37. J Microbiol. 2014 Jul:52(7):581-9.2014.

Currie s; et al. The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus. PLoS ONE 8(8): e73659.

Yang; et al. Antmicrobial peptide LL-37 circulating levels in chronic obstruction pulmonary disease patients with high risk of frequent exacerbations. J Thorac Dis. 2015 Apr, 7(4):740-745.

Kusaka; et al. Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease. Clin Exp Immunol. 2018 Jan;19(11):96-106 doi:10.1111/cei. 13047. Epub 2017 Sep 28.

Lande; et al. The antimicrobial peptide LL-37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014 Dec 3;5:5621. Doi 10.1038.

Heilborn JD; et al. Topical treatment with the vitamin D analogue calipotriol enhances the upregulation of the antimicrobial protein hCAP18/LL-37 during wounding in human skin in vivo. Exp Dermatol. 2010 Apr;19(4):332-8.

Ren; et al. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res. 2012 Dec 15; 72(24): 6512-6523, 2012 Oct 24.

Wu WK; et al. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J Cell Physiol. 2010 Apr,223(1):178-86.

Kahlenberg J; Kaplan M. Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease. Journal of Immunology. Jan 15, 2018.